REGN Regeneron Pharmaceuticals, Inc.
Price Chart
Executive Summary
Regeneron and Telix announced a collaboration to co-develop and co-commercialize next-generation radiopharmaceutical therapies, with Regeneron paying $40 million upfront for access to four initial programs. The 50/50 cost and profit-sharing model marks Regeneron's strategic entry into radiopharmaceuticals, combining its antibody expertise with Telix’s radiopharmaceutical infrastructure.
Key Financial Metrics
Actionable Insight
Traders should monitor progress in the radiopharmaceutical pipeline, especially early clinical data readouts. The 50/50 structure enhances Regeneron's long-term revenue potential compared to traditional licensing deals, but also increases R&D spend. Any opt-out by Telix on co-funding would shift the risk to Regeneron but reduce future profit share.
Key Facts
- Regeneron pays Telix $40 million upfront for four initial radiopharmaceutical programs.
- Partnership operates under a 50/50 cost and profit-sharing model, with co-development and co-commercialization rights.
- Telix retains option to opt-out of co-funding and instead receive up to $535 million per program in milestones plus low double-digit royalties.
- Regeneron gains option to expand the collaboration to four additional programs with further upfront payments.
- Joint development of radio-diagnostics to support patient selection and treatment monitoring.
Financial Impact
$40 million upfront payment; potential future milestone payments up to $2.1 billion aggregate; 50% shared commercialization costs and profits.
Risk Factors
- Clinical failure risk in early-stage radiopharmaceutical programs.
- Potential for Telix to opt-out of co-funding, increasing Regeneron's financial burden.
- Regulatory delays in novel radiopharmaceutical approvals.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3272314 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 31, 2026
9d ago
|
ANALYST-UPGRADE
| $810.25 $752.29 | ▼ −7.15% | ▼ −7.28% | $611.34 (−24.55%) |
|
May 21, 2026
19d ago
|
Press Release
| $638.53 $600.65 | ▼ −5.93% | ▼ −7.59% | $611.34 (−4.26%) |
|
May 18, 2026
22d ago
|
ANALYST-DOWNGRADE
| $629.34 $632.17 | ▼ −0.45% | ▲ +1.17% | $611.34 (+2.86%) |
|
May 18, 2026
22d ago
|
Press Release
| $629.34 $632.17 | ▲ +0.45% | ▼ −1.17% | $611.34 (−2.86%) |
|
May 16, 2026
25d ago
|
Press Release
| $629.34 $632.17 | ▼ −0.45% | ▲ +1.17% | $611.34 (+2.86%) |
|
May 15, 2026
25d ago
|
Press Release
| $696.20 $638.53 | ▼ −8.28% | ▼ −9.25% | $611.34 (−12.19%) |
|
May 1, 2026
5w ago
|
ANALYST-UPGRADE
| $810.25 $752.29 | ▼ −7.15% | ▼ −7.28% | $611.34 (−24.55%) |
|
Apr 24, 2026
6w ago
|
DEFA14A
| $744.35 $709.19 | ▼ −4.72% | ▼ −5.12% | $611.34 (−17.87%) |
|
Apr 21, 2026
7w ago
|
Press Release
| $747.15 $729.36 | ▼ −2.38% | ▼ −3.46% | $611.34 (−18.18%) |
|
Apr 13, 2026
8w ago
|
Press Release
| $745.61 $749.26 | ▲ +0.49% | ▼ −2.81% | $611.34 (−18.01%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access